Search results for "Conventional PCI"

showing 10 items of 121 documents

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting ste…

2008

Objectives: To investigate the long-term prognostic implications of complete versus incomplete revascularization in multivessel coronary artery disease (MVD) patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Background: Coronary artery bypass grafting (CABG) in patients with MVD provides better outcomes when complete revascularization is achieved. There is a paucity of data on the outcomes of complete versus incomplete revascularization of MVD patients undergoing PCI, and currently there is no data available with DES. Methods: Patients with MVD undergoing PCI with DES (sirolimus- or paclitaxel-eluting stent) were included. Comparisons of long-term o…

Malemedicine.medical_specialtyTime FactorsPaclitaxelmedicine.medical_treatmentPopulationCoronary Artery DiseaseKaplan-Meier EstimateRevascularizationRisk AssessmentCoronary artery diseaseInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingMyocardial infarctionRegistriesAngioplasty Balloon CoronaryeducationAgedProportional Hazards ModelsRetrospective StudiesSirolimuseducation.field_of_studyMultivessel diseasebusiness.industryStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRevascularization strategy.Treatment OutcomeDrug-eluting stentCardiovascular DiseasesConventional PCICardiologyFemaleDrug-eluting stentCardiology and Cardiovascular MedicinebusinessCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct

Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propen…

2018

Objectives We sought to determine the 1-year clinical follow-up in patients treated with the thin strut (71 μm) bioabsorbable polymer-coated sirolimus-eluting stent (BP-SES) vs durable coating everolimus eluting stent (DP-EES) in daily clinical routine. Background Presence of durable polymers may be associated with late/very late stent thrombosis occurrence and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. Methods Interventional Cardiology Network Registry is a prospective, multicenter, observational registry of 21,400 consecutive patients treated with PCI since 2010. We analyzed 4,670 patients treated …

Malemedicine.medical_specialtyTime FactorsPolymersmedicine.medical_treatmentCoronary Artery Disease030204 cardiovascular system & hematologyProsthesis DesignRisk Assessment03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingEverolimusRegistries030212 general & internal medicineMyocardial infarctionAngioplasty Balloon CoronaryPropensity ScoreAgedRetrospective StudiesSirolimusInterventional cardiologybusiness.industryStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeBioresorbable polymerSirolimusConventional PCIPropensity score matchingFemaleObservational studyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Reperfusion strategy in Europe: temporal trends in performance measures for reperfusion therapy in ST-elevation myocardial infarction

2010

Aims The rate and type of reperfusion, as well as time delays to reperfusion are directly associated with mortality and are established as performance measures (PMs) in the treatment of ST elevation myocardial infarction (STEMI). To date, little information exists about PMs for reperfusion in clinical practice in Europe and their temporal changes. Methods and results Using the Euro Heart Survey ACS-III data set (2 years of inclusions between 2006 and 2008, 138 centres in 21 countries), we selected patients with STEMI eligible for reperfusion therapy. Recorded variables corresponded to the CARDS data set. The rate and type of reperfusion, as well as door to needle and door to artery times we…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionHemorrhageMyocardial ReperfusionReperfusion therapyFibrinolytic AgentsRecurrenceAngioplastyInternal medicinemedicineHumansMyocardial infarctionAngioplasty Balloon CoronaryStrokebusiness.industryST elevationPercutaneous coronary interventionMiddle Agedmedicine.diseaseEuropeHospitalizationStrokeTreatment OutcomeConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFibrinolytic agentEuropean Heart Journal
researchProduct

Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Prel…

2009

BACKGROUND: beta-blockers in ST-segment elevation myocardial infarction (STEMI) are indicated for patients without a contraindication, particularly in patients with high heart rates (HR) or blood pressures. Epidemiological studies have shown that elevated HR represents a risk factor for cardiovascular morbidity. The study investigates the feasibility, tolerability, and the effects after 30 days of follow-up of ivabradine (IVA) versus metoprolol (METO) in early phases of anterior STEMI reperfused by percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with a first anterior STEMI, Killip class I-II, an acceptable echocardiographic window, and admitted within 4hours of the o…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsVentricular Dysfunction LeftDouble-Blind MethodInternal medicineejection fraction end systole volume ivabradinemedicineHumansIvabradinecardiovascular diseasesMyocardial infarctionAgedMetoprololKillip classEjection fractionbusiness.industryPercutaneous coronary interventionBenzazepinesMiddle Agedmedicine.diseasesurgical procedures operativeConventional PCICardiologyMyocardial infarction complicationsFemaleCardiology and Cardiovascular MedicinebusinessIvabradineFollow-Up StudiesMetoprololmedicine.drugJournal of Cardiac Failure
researchProduct

Prognostic value of ST-segment resolution after rescue percutaneous coronary intervention. Data from the RICO survey

2008

Objectives: The goal of the present study was to test the impact of ST segment resolution (STR) after rescue percutaneous coronary intervention (PCI) on the short-term prognosis. Background: The prognostic value of STR after rescue PCI for acute ST elevation myocardial infarction (STEMI) remains undetermined. Methods: From the French regional database, we analyzed 168 consecutive patients with STEMI and failed lysis, defined by <50 percent STR, who underwent rescue PCI. Patients were classified into two groups according to the degree of STR from the maximal ST-elevation measured on the single worst ECG lead before lysis and after rescue PCI: the without STR group (<50% STR) vs. the with STR…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionRisk AssessmentElectrocardiographyCoronary CirculationInternal medicineOdds RatiomedicineHumansST segmentThrombolytic TherapyRadiology Nuclear Medicine and imagingProspective StudiesRegistriesTreatment Failurecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryProspective cohort studyAgedIntra-Aortic Balloon Pumpingmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle AgedPrognosismedicine.diseaseeye diseasesSurgeryTreatment OutcomeCardiovascular DiseasesHealth Care SurveysConventional PCICardiologyFemaleStentsFranceCardiology and Cardiovascular MedicinebusinessElectrocardiographyTIMICatheterization and Cardiovascular Interventions
researchProduct

Feasibility of Implanting 50-60 mm-Tapered Drug Eluting Stents in Chronic Total Occlusions.

2018

Abstract Background Percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) usually involves multiple overlapping stents implantation to cover long coronary segments. A higher rate of restenosis has been described with stent overlapping. Recently, new long tapered stents emerged as a potential tool for treating long coronary lesions. Feasibility of using these new devices for the CTO PCI has not been described. The aim of this work was to describe our initial experience with 50 and 60 mm-long tapered sirolimus-eluting stents (SES) in CTO PCI. Methods We included 54 consecutive patients who underwent a CTO PCI and in whom an attempt to implant a 50 or 60 mm-long tapered SE…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentTarget vessel030204 cardiovascular system & hematologyProsthesis DesignCoronary Restenosis03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRestenosismedicineHumanscardiovascular diseases030212 general & internal medicineVascular PatencyAgedRetrospective StudiesSirolimusbusiness.industryPercutaneous coronary interventionStentCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgerysurgical procedures operativeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseFeasibility StudiesFemaleImplantCardiology and Cardiovascular MedicinebusinessCardiovascular revascularization medicine : including molecular interventions
researchProduct

Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction

2017

Abstract Objectives The study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%). Background Data regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported. Methods The authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%). Results A total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was pr…

Malemedicine.medical_specialtyanimal structuresTime Factorsmedicine.medical_treatment610 Medicine & healthKaplan-Meier Estimate030204 cardiovascular system & hematologyCoronary AngiographyDisease-Free SurvivalVentricular Function Left2705 Cardiology and Cardiovascular Medicinechronic total occlusion; ischemic LV dysfunction; left ventricular ejection fraction; PCI; Cardiology and Cardiovascular Medicinechronic total occlusionischemic LV dysfunctionleft ventricular ejection fractionPCI03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsInternal medicinemedicineHumansIn patientcardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective Studieschronic total occlusionAgedProportional Hazards ModelsEjection fractionbusiness.industryPercutaneous coronary interventionleft ventricular ejection fractionPCIStroke VolumeRecovery of FunctionMiddle AgedSurgeryEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseCardiology10209 Clinic for CardiologyFemalebusinessCardiology and Cardiovascular Medicineischemic LV dysfunction
researchProduct

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct